Page last updated: 2024-10-14

fucoxanthinol

Description

fucoxanthinol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11273547
SCHEMBL ID17557876
MeSH IDM0463176

Synonyms (7)

Synonym
fucoxanthinol
LMPR01070055
7176-02-5
fucoxanthinol, analytical standard
SCHEMBL17557876
8-oxo-trans-neoxanthin
DTXSID201347243

Research Excerpts

Overview

Fucoxanthinol (FxOH) is a marine carotenoid metabolite with potent anti-cancer activity. It accumulates in abundance in edible brown algae and promises human health benefits.

ExcerptReference
"Fucoxanthinol (FXOH) is a marine carotenoid from brown seaweeds with various beneficial effects."( Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Chen, W; Fang, H; Hong, Z; Jin, W; Li, L; Yang, L; Yi, Z; Zhang, G; Zhang, Y, 2020
)
"Fucoxanthinol (FxOH) is a marine carotenoid metabolite with potent anti-cancer activity. "( Effect of Fucoxanthinol on Pancreatic Ductal Adenocarcinoma Cells from an
Kojima, H; Kojoma, M; Kubota, A; Maeda, H; Miyashita, K; Murase, W; Mutoh, M; Nishizaka, Y; Takahashi, M; Tanaka, T; Terasaki, M,
)
"Fucoxanthinol (FxOH) is a strong anticancer metabolite of fucoxanthin that accumulates in abundance in edible brown algae and promises human health benefits. "( Glycine and succinic acid are effective indicators of the suppression of epithelial-mesenchymal transition by fucoxanthinol in colorectal cancer stem-like cells.
Endo, T; Hamada, J; Kudoh, S; Maeda, H; Mima, M; Miyashita, K; Mutoh, M; Osada, K; Terasaki, M, 2018
)

Bioavailability

The method was applied successfully in a pharmacokinetic study of fucoxanthinol. The resulting bioavailability was calculated.

ExcerptReference
" By comparing the present results with those of a previous study using mice, we found that the bioavailability and metabolism of fucoxanthinol differ between human subjects and mice."( Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract.
Azuma, T; Hashimoto, T; Kanazawa, K; Komoto, A; Maoka, T; Mizuno, M; Nishitani, Y; Ozaki, Y; Tanino, Y; Yoshida, M, 2012
)
" The method was applied successfully in a pharmacokinetic study and the resulting oral fucoxanthin bioavailability calculated."( Simultaneous Determination of Fucoxanthin and Its Deacetylated Metabolite Fucoxanthinol in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
Fang, H; Hong, Z; Liu, R; Wen, H; Wu, H; Yi, R; Zhang, Y, 2015
)
" In this study, in vivo and in vitro FX bioavailability were investigated using FX-fortified milk (FX-SM and FX-WM) and microalga Phaeodactylum tricornutum biomass (Pt-powder)."( Fucoxanthin bioavailability from fucoxanthin-fortified milk: In vivo and in vitro study.
Kim, JH; Kim, SM; Lee, JK; Mok, IK; Pan, CH, 2018
)
" The method was applied successfully in a pharmacokinetic study of fucoxanthinol and the resulting bioavailability was calculated."( Determination of fucoxanthinol in rat plasma by liquid chromatography-tandem mass spectrometry.
Chen, W; Hong, Z; Huang, M; Jin, W; Lin, J; Sun, J; Yan, G; Yang, L; Zhang, Y, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
diadinoxanthin and fucoxanthin biosynthesis013

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (20.45)29.6817
2010's25 (56.82)24.3611
2020's10 (22.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.04%)5.53%
Reviews3 (6.12%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (91.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]